Bibliography
- Citrome L. Efficacy versus effectiveness. In: Kattan MW, editor. Encyclopedia of Medical Decision Making. Sage Publications, Thousand Oaks, California, USA; 2009. p. 431-3
- Citrome L. Evidence-based medicine: it's not just about the evidence. Int J Clin Pract 2011;65:634-5
- Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10:1917-28
- US Food and Drug Administration. Structured Product Labeling Resources. Available from: http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm [Last accessed 24 May 2011]
- US Food and Drug Administration. The FDA Announces New Prescription Drug Information Format. Last updated 2009 November 02. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm188665.htm [Last accessed 24 May 2011]
- Mitka M. Drug package inserts get mixed reception. JAMA 2006;295(10):1110-11
- European Medicines Agency. Home Page. Available from: http://www.ema.europa.eu/ema [Last accessed 24 May 2011]
- Goodnick PJ. Higher than Physician's Desk Reference (US) doses on atypical antipsychotics. Expert Opin Drug Saf 2005;4:653-68
- Steinmetz KL, Coley KC, Pollock BG. Assessment of geriatric information on the drug label for commonly prescribed drugs in older people. J Am Geriatr Soc 2005;53:891-4
- de Leon J. Highlights of drug package inserts and the website DailyMed. The need for further improvement in package inserts to help busy prescribers. J Clin Psychopharmacol 2011;31:263-5
- Novartis. Clozaril (clozapine). Revised December 2010. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf [Last accessed 24 May 2011]
- Janssen. Risperdal (risperidone). Revised April 2011. Available from: http://www.risperdal.com/sites/default/files/shared/pi/risperdal.pdf [Last accessed 10 August 2011]
- Eli Lilly. Zyprexa (olanzapine). Revised June 2011. Available from: http://pi.lilly.com/us/zyprexa-pi.pdf [Last accessed 10 August 2011]
- AstraZeneca. Seroquel (quetiapine). Revised July 2011. Available from: http://www1.astrazeneca-us.com/pi/Seroquel.pdf [Last accessed 10 August 2011]
- AstraZeneca. Seroquel XR (quetiapine extended release). Revised July 2011. Available from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf [Last accessed 10 August 2011]
- Pfizer. Geodon (ziprasidone). Revised December 2010. Available from: http://www.pfizer.com/files/products/uspi_geodon.pdf [Last accessed 10 August 2011]
- Bristol-Myers Squibb. Abilify (aripiprazole). Revised February 2011. Available from: http://www.abilify.com/pdf/pi.aspx [Last accessed 10 August 2011]
- Janssen. Invega (paliperidone). Revised April 2011. Available from: http://janssencns.com/sites/default/files/pdf/invega/invega.pdf [Last accessed 10 August 2011]
- Novartis. Fanapt (iloperidone). Revised April 2011. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf [Last accessed 10 August 2011]
- Merck. Saphris (asenapine). Revised October 2011. Available from: http://www.spfiles.com/pisaphrisv1.pdf [Last accessed 7 October 2011]
- Sunovion. Latuda (lurasidone). Revised October 2010. Available from: http://www.latuda.com/LatudaPrescribingInformation.pdf [Last accessed 10 August 2011]
- Eli Lilly. Symbyax (olanzapine and fluoxetine). Revised April 2011. Available from: http://pi.lilly.com/us/symbyax-pi.pdf [Last accessed 10 August 2011]
- US Food and Drug Administration. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. 2011 February 22. Last updated 2011 March 29. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm [Last accessed 27 May 2011]
- Citrome L. Drug safety evaluation of ziprasidone. Expert Opin Drug Saf 2011;10:437-48
- Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialized second-generation antipsychotic. Int J Clin Pract 2010;64:707-18
- Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009;4:229-37
- Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010;122:39-48
- Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999;57:507-33
- Mamah D, Wang L, Barch D, Structural analysis of the basal ganglia in schizophrenia. Schizophr Res 2007;89:59-71
- Scheepers FE, de Wied CC, Hulshoff Pol HE, The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 2001;24:47-54
- Brebion G, Bressan RA, Amador X, Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med 2004;34:369-74
- Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004;9(Suppl 11):6-14